This website is intended for U.S. Healthcare Professionals.

Indication
REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Indication
REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

REVLIMID® and associated logos are registered trademarks of Celgene Corporation, a Bristol Myers Squibb company. Access Support® and the related logo are registered trademarks of Bristol-Myers Squibb Company.

REVLIMID®, POMALYST®, POMALYST REMS®, IMiD®, and associated logos are registered trademarks of Celgene Corporation, a Bristol Myers Squibb company. Access Support® and the related logo are registered trademarks of Bristol-Myers Squibb Company. Darzalex, Darzalex Faspro, and relevant portions of the ISI are property of Janssen Biotech, Inc.

© 2023 Bristol-Myers Squibb Company.

2003-US-2300029  07/23

Back
to Top